Wall Street chugged mostly higher in premarket trading as Chinese and U.S. officials begin a second day of trade talks.

Novo Nordisk slashed its full-year 2025 guidance on Tuesday, sending its shares tumbling more than 28% in premarket trading. The company also separately announced that Maziar Mike Doustdar has been ...

Novo Nordisk (NVO) stock falls as the company names a new CEO and cuts outlook citing pressure on obesity drug sales. Eli ...

Novo Nordisk cut its full-year guidance as U.S. sales continue to be hurt by copycat versions of its blockbuster Wegovy ...

Novo Nordisk A/S lowered its financial forecast in a surprise update that cited lagging sales of its weight-loss drug Wegovy, as the company fights to regain its leading position in the obesity market ...

Novo Nordisk, known for its obesity drug Wegovy, announced a reduction in its full-year sales and operating profit forecasts.

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk stock fell after the drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its ...

In European equities on Tuesday, the CAC 40 in Paris gained 0.6%, while the DAX 40 in Frankfurt was up 1.4%. They had ended down 0.4% and 1.0% on Monday.

Bagsværd, Denmark, 29 July 2025 - Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of 2025 and updated full-year sales and opera ...

Novo Nordisk has revised its 2025 sales and profit expectations downward for the second time, facing tough competition from ...

Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of ...